Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07188441

PHASE2

Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.

Sponsor: Chengcheng Guo

View on ClinicalTrials.gov

Summary

This trial is a prospective single arm intervention study, conducting clinical research on marketed drugs. Adverse drug reactions are controllable and the risk is low, with an estimated total of 40 cases. The main objective is to evaluate the safety and efficacy of teniposide combined with cisplatin in the treatment of newly diagnosed central malignant germ cell tumors, and to conduct drug monitoring on subjects to explore potential biomarkers for predicting therapeutic efficacy. It is expected to ultimately achieve the goal of prolonging the overall survival of patients, while providing more guidance for the screening of the best treatment population and biological predictive markers.

Official title: A Single-center, Single-arm, Open-label Study of the Combination of Teniposide Injection and Cisplatin in the Treatment of Newly Diagnosed Patients With Central Malignant Germ Cell Tumors.

Key Details

Gender

All

Age Range

5 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-08-13

Completion Date

2026-12

Last Updated

2025-09-23

Healthy Volunteers

Conditions

GCT Germ Cell Tumor Central Malignant Germ Cell Tumor

Interventions

DRUG

Teniposide Injection

teniposide 300mg/m2 for 5 days, cisplatin 75mg/m2 for 5 days

Inclusion Criteria: * Must have at least one measurable lesion defined by RANO criteria * The initial diagnosis has been confirmed as central malignant germ cell tumor * Expected survival period ≥ 6 months * Absolute neutrophil ≥1.0×10\^9/L; Platelet ≥100.0×10\^9/L * Aspertate aminotransferase and alanine aminotransferase ≤2.5×Upper limit of normal * total bilirubin ≤1.5×Upper limit of normal * Electronic Case Report of Form≥70mL/min/1.73m\^2 * Estimated glomerular filtration rate ≥ 70 mL/min/1.73 m² or normal serum creatinine (Cr) * Women and men with fertility must agree to use appropriate contraceptive methods (hormones or barrier therapy or abstinence) during the study period and within 3 months after the last dose; The pregnancy test of female subjects of childbearing age within 7 days before administration must be negative * Willing and able to read, understand, and sign written informed consent, parents/guardians of child or adolescent subjects have the ability to understand, agree, and sign research informed consent forms and applicable child consent forms before initiating any protocol related procedures Exclusion Criteria: * Patients undergoing any other anti-cancer experimental treatment * Individuals with a history of severe allergies or allergies to any component of the drugs in the past * Previous or concurrent active cardiovascular diseases with clinical significance, including congenital heart disease or pericardial disease, history of heart failure, myocardial infarction, coronary heart disease, heart valve disease, cardiomyopathy, and arrhythmia * Patients with Magnetic Resonance Imaging contraindications * Those who need to receive live virus vaccine during administration * Serious complications and/or underlying diseases * Individuals with poor control of hypertension (under standardized blood pressure reduction protocols, systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg) * Uncontrolled systemic bacterial, viral, or fungal infections * Patients infected with Human Immunodeficiency Virus(HIV) or syphilis * Patients who have undergone organ transplantation in the past * Pregnant or lactating women * Researchers believe that there are other factors that are not suitable for participating in the experiment

Locations (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China